...
机译:VEGF仍然是晚期胰腺癌(APCA)中有趣的靶标:贝伐单抗,吉西他滨和5-氟尿嘧啶输注的多机构II期研究的结果
1Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus 2Center for Biostatistics, The Ohio State University, Columbus 3Comprehensive Cancer Center, The Ohio State University, Columbus 4Department of Surgery, Division of General Surgery, The Ohio State University Medical Center, Columbus 5Department of Surgery, Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus 6Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA;
机译:VEGF仍然是晚期胰腺癌(APCA)中有趣的靶标:贝伐单抗,吉西他滨和5-氟尿嘧啶输注的多机构II期研究的结果
机译:I期研究针对晚期癌症和主要肝转移患者的nab-紫杉醇联合静脉注射吉西他滨和贝伐单抗的肝动脉输注。
机译:肝癌肝动脉输注与静脉胚轴和贝伐单抗的肝动脉输注治疗晚期癌症和主要肝转移患者的肝动脉输注。
机译:TS-1在晚期胃癌中的多机构期II研究
机译:VEGF仍然是晚期胰腺癌(APCA)中有趣的靶标:贝伐单抗吉西他滨和5-氟尿嘧啶输注的多机构II期研究的结果
机译:肝动脉输注Nab-紫杉醇与静脉胚轴和贝伐单抗的肝动脉输注研究患者晚期癌症和主要肝转移患者